Eli Lilly (LLY) says it will present new data on Foundayo, retatrutide and eloraTZP at EASD 2026; delivered substantial weight loss and A1C improvements in obesity and type 2 diabetes

Abstract and late-breaker presentations at major diabetes conferences are the standard cadence for the incretin space, and the pattern has been consistent: data of this kind moves the tape twice, once on the abstract headline and again on the full presentation, with the second move frequently a fade or an extension depending on whether the detail matches the topline. The mechanism here is the obesity and type 2 diabetes franchise race, where Lilly and its principal peptide competitor trade as a quasi-duopoly and each readout is priced relative to the rival's established efficacy bar rather than in isolation; pipeline assets like triple-agonist and oral candidates tend to be valued on the gap to incumbents, not absolute numbers. A conference presentation is not a regulatory event, so the weight-loss and glycaemic claims carry no approval implications on their own; what matters for precedent is how the data position the assets for pivotal filings and label breadth. Points worth watching are the placebo-adjusted magnitudes against the existing class benchmark, tolerability and discontinuation rates, and any commentary on manufacturing or supply, which has historically been the binding constraint in this franchise. As a promotional-style company headline ahead of the actual session, the informational content is thin until the data are on the screen.